Summary
Although primary brain tumors (PBTs) are generally considered to be a multifactorial disorder, understanding the genetic basis and etiology of the disease is essential for PBT risk assessment. Understanding of the genetic susceptibility for PBT has come from studies of rare genetic syndromes, linkage analysis, family aggregation, early-onset pediatric cases, and mutagen sensitivity. There are currently no effective markers to assess biological dose of exposures and genetic heterogeneity. The priorities recently recommended by the Brain Tumor Epidemiology Consortium emphasized the need for expanding research in genetics and molecular epidemiology. In this article, we review the literature to identify molecular epidemiologic case-control studies of PBTs that were hypothesis-driven and focused on four hypothesized candidate pathways: DNA repair, cell cycle, metabolism, and inflammation. We summarize the results in terms of genetic associations of single nucleotide polymorphisms of these pathways. We also discuss future research directions based on available evidence and technologies, and conclude that high resolution whole genome approach with significantly large sample size could rapidly advance our understanding of the genetic etiology of PBTs. Literature searches were done on PubMed in March 2009 with the terms glioma, glioblastoma, brain tumor, association, and polymorphism, and we only reviewed English language publications.
Article PDF
Similar content being viewed by others
References
Inskip P, Linet M, Heineman E. Etiology of brain tumors in adults. Epidemiol Rev 1995;17: 382–414.
Wrensch M, Minn Y, Chew T, Bondy M, Berger M. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4: 278–299.
Central Brain Tumor Registry of the United States. Available at: http://www.CBTRUS.org. Accessed April 16, 2009.
Melean G, Sestini R, Ammannati F, Papi L. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin 2004;129: 74–84.
Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Long-term follow-up for brain tumor development following childhood exposure to ionizing radiation for tinea capitis. Radiat Res 2005;163: 424–432.
Kruglyak L. The road to genome-wide association studies. Nat Genet 2008;9: 314–318.
Easton D, Pooley K, Dunning A, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447: 1087–1093.
Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39: 631–637.
Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007;39: 984–988.
Yeager M, Orr N, Hayes R, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39: 645–649.
Zanke B, Greenwood C, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007;39: 989–994.
Melean G, Sestini R, Ammannati F, et al. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin 2004;129: 74–84.
Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396: 643–649.
Beckman R, Loeb L. Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005;15: 423–435.
Patel A, van Meyel D, Mohapatra G, et al. Gliomas in families: chromosomal analysis by comparative genomic hybridization. Cancer Genet Cytogenet 1998;100: 77–83.
Schwartzbaum J, Fisher J, Aldape K, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006;2: 494–503.
Van der Weil HJ. Inheritance of glioma. New York: Elsevier; 1960.
Metzel E. Betrachtungen zur Genetik der famili_ren Gliome. Acta Genet Med Gemellol (Roma) 1964;13: 124–131.
Choi N, Schuman L, Gullen W. Epidemiology of primary central nervous system neoplasms. II. Case control study. Am J Epidemiol 1970;91: 467–485.
Hill D, Inskip P, Shapiro W, et al. Cancer in first-degree relatives and risk of glioma in adults. Cancer Epidemiol Biomarkers Prev 2003;12: 1443–1448.
Malmer B, Gronberg H, Bergenheim A, et al. Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study. Int J Cancer 1999;81: 366–370.
Malmer B, Henriksson R, Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 2003;106: 260–263.
Scheurer M, Etzel C, Liu M, et al. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 2007;16: 2491–2495.
Tachibana I, Smith J, Sato K, et al. Investigationof germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. Am J Med Genet 2000;92: 136–141.
Paunu N, Syrjakoski K, Sankila R, et al. Analysis of p53 tumor suppressor gene in families with multiple glioma patients. J Neuro oncol 2001;55: 159–165.
Paunu N, Lahermo P, Onkamo P, et al. A novel low-penetrance locus for familial glioma at 15q23-q26.3. Cancer Res 2002;62: 3798–3802.
Bredel M, Bredel C, Juric D, et al. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 2005;65: 4088–4096.
Wong K, Tsang Y, Chang Y, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 2006;66: 11172–11178.
Zhou K, Liu Y, Zhang H, et al. XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer 2009;124: 2948–2953.
Kiuru A, Lindholm C, Heinavaara S, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neuro Oncol 2008;88: 135–142.
Liu Y, Zhou K, Zhang H, et al. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. Human Mut 2008;29: 381–389.
Liu Y, Zhang H, Zhou K, et al. Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. Carcinogenesis 2007;28: 1906–1913.
Wang L, Bondy M, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 2004;64: 5560–5563.
Chang J, Yeh R, Wiencke J, et al. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 2008;17: 1368–1373.
Liu Y, Scheurer M, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 2009;18: 204–214.
Chen P, Wiencke J, Aldape K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000;9: 843–847.
Wrensch M, Kelsey K, Liu M, et al. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro-Oncol 2005;7: 495–507.
Caggana M, Kilgallen J, Conroy J, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 2001;10: 355–360.
Yang P, Kollmeyer T, Buckner K, et al. Polymorphisms in GLT-SCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 2005;103: 2363–2372.
Felini M, Olshan A, Schroeder J, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiol 2007;29: 55–58.
Inoue R, Isono M, Abe M, et al. A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma. Neurol Res 2003;25: 875–879.
Bethke L, Webb E, Murray A, et al. Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Human Mol Genet 2008;17: 800–805.
Pinto G, Yoshioka F, Silva R, et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res 2008;7: 207–216.
Sadetzki S, Flint-Richter P, Starinsky S, et al. Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev 2005;14: 969–976.
Leone P, Mendiola M, Alonso J, et al. Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker. BMC Cancer 2003;3: 6.
Parhar P, Ezer R, Shao Y, et al. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 2005;137: 98–103.
Chen P, Iavarone A, Fick J, et al. Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 1995;82: 106–115.
Zhou X, Sanson M, Hoang-Xuan K, et al. Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas. Ann Neurology 1999;46: 913–916.
Hayashi Y, Yamashita J, Watanabe T. Molecular genetic analysis of deep-seated glioblastomas. Cancer Genet Cytogenet 2004;153: 64–68.
Bhowmick D, Zhuang Z, Wait S, et al. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64: 1220–1223.
Carpentier C, Laigle-Donadey F, Marie Y, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurol 2006;67: 872–874.
Costa B, Ferreira P, Costa S, et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007;13: 2621–2626.
Vauleon E, Auger N, Benouaich-Amiel A, et al. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet 2007;172: 33–37.
Hayashi Y, Ueki K, Waha A, et al. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7: 871–875.
Barbosa K, Oba-Shinjo S, Uno M, et al. Association of EGFR c.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study. Int J Biol Markers 2008;23: 140–146.
Smith J, Tachibana I, Passe S, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93: 1246–1256.
Kato H, Fujimura M, Kumabe T, et al. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 2004;11: 37–41.
Tunca B, Bekar A, Cecener G, et al. Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neuro Oncol 2007;82: 263–269.
Khatri R, Navaratne K, Weil R. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J Neurosurg 2008;109: 842–848.
Tsuiki H, Nishi T, Takeshima H, et al. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol Med Chir 2007;47: 203–208.
Godfraind C, Rousseau E, Ruchoux M, et al. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 2003;29: 462–471.
Gao L, Liu L, van Meyel D, et al. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma. Clin Cancer Res 1997;3: 977–981.
Tada K, Kochi M, Saya H, et al. Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. Neuro Oncol 2003;5: 228–234.
Gallia G, Rand V, Siu I, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4: 709–714.
McCready J, Broaddus W, Sykes V, et al. Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer 2005;117: 781–785.
Lu Z, Wang Y, Zhang Q, et al. Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res 2006;1118: 6–1112.
Chen P, Wiencke J, Conway K, et al. Lack of association of rare alleles in the FIRAS variable number of tandem repeats (VNTR) region with adult glioma. Neuro Oncol 2000;2: 120–124.
Bethke L, Sullivan K, Webb E, et al. The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 2008;17: 987–989.
Rodero M, Marie Y, Coudert M, et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Gin Oncol 2008;26: 5957–5964.
Rajaraman P, Wang S, Rothman N, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 2007;16: 1655–1661.
De Roos A, Rothman N, Brown M, et al. Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro Oncol 2006;8: 145–155.
De Roos A, Rothman N, Inskip P, et al. Genetic polymorphisms in GSTM1,-P1,-T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 2003;12: 14–22.
Rajaraman P, Hutchinson A, Rothman N, et al. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 2008;10: 709–715.
Ezer R, Alonso M, Pereira E, et al. Identification of glutathione S-trausferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J Neuro Oncol 2002;59: 123–134.
Schwartzbaum J, Ahlbom A, Lonn S, et al. An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 2007;16: 559–565.
Trizna Z, de Andrade M, Kyritsis A, et al. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol Biomarkers Prev 1998;7: 553–555.
Peters E, Kelsey K, Wiencke J, et al. NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiol Biomarkers Prev 2001;10: 151–152.
Kafadar A, Ergen A, Zeybek U, et al. Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Bioche Funct 2006;24: 455–460.
Searles Nielsen S, Mueller B, De Roos A, et al. Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect 2005;113: 909–913.
Bethke L, Webb E, Murray A, et al. Functional polymorphisms in folate metabolism genes influence the risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008;17: 1195–1202.
Semmler A, Simon M, Moskau S, et al. The methionine synthase polymorphism c.2756A>G alters susceptibility to glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 2006;15: 2314–2316.
Wrensch M, Kelsey K, Liu M, et al. Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol Biomarkers Prev 2004;13: 461–467.
Miller K, Kelsey K, Wiencke J, et al. The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 2005;25: 85–90.
Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14: 1784–1790.
Huncharek M, Kupelnick B, Wheeler L. Dietary cured meat and the risk of adult glioma: a ineta-analysis of nine observational studies. J Environ Pathol, Toxicol Oncol 2003;22: 129–137.
Scheurer M, Amirian E, Cao Y, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res 2008;14: 6640–6646.
Wiemels J, Wiencke J, Kelsey K, et al. Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol Biomarkers Prev 2007;16: 1229–1235.
Schwartzbaum J, Ahlbom A, Malmer B, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 2005;65: 6459–6465.
Schwartzbaum J, Ahlbom A, Lonn S, et al. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev 2007;16: 2448–2454.
Brenner A, Butler M, Wang S, et al. Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 2007;28: 2543–2547.
Amirian E, Y Liu, Scheurer M, et al. Interaction among genetic variants in inflammation pathway genes and asthma in glioma susceptibility. Neuro Oncology. In press 2009.
Frigerio S, Ciusani E, Pozzi A, et al. Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Cancer Genet Cytogenet 1999;109: 172–174.
Linos E, Raine T, Alonso A, et al. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007;99: 1544–1550.
Parsons D, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321: 1807–1812.
Yan H, Parsons D, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;19: 360: 765–773.
Carpentier C, Lejeune J, Gros F, et al. Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neuro Oncol 2007;84: 249–253.
Onilude O, Lusher M, Lindsey J, et al. APC and CTNNB1 mutations are rare in sporadic ependymomas. Cancer Genet Cytogenet 2006;168: 158–161.
Lonn S, Rothman N, Shapiro W, et al. Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol 2008;10: 553–559.
Rajaraman P, Stewart P, Samet J, et al. Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 2006;15: 2514–2520.
Rajaraman P, Schwartz B, Rothman N, et al. Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect 2005;113: 1209–1211.
Bardakci F, Arslan S, Bardakci S, et al. Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol 2008;134: 109–114.
Malmer B, Adatto P, Armstrong G, et al. GLIOGENE-an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev 2007;16: 1730–1733.
McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455: 1061–1068.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gu, J., Liu, Y., Kyritsis, A.P. et al. Molecular epidemiology of primary brain tumors. Neurotherapeutics 6, 427–435 (2009). https://doi.org/10.1016/j.nurt.2009.05.001
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2009.05.001